On May 18, 2017 Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, reported that the Company will present preclinical data on SY-1425, its oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with hypomethylating agents and anti-CD38 therapies in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 22nd Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) taking place June 22-25 in Madrid, Spain (Press release, Syros Pharmaceuticals, MAY 18, 2017, View Source;p=irol-newsArticle&ID=2273936 [SID1234519251]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the presentation are as follows:
Date & Time: Friday, June 23, from 5:15 – 6:45 p.m. CEST
Presentation Title: Mechanistically Informed Combinations of SY-1425, a Potent and Selective RARα Agonist, with Hypomethylating or Anti-CD38 Targeted Agents in AML and MDS
Session Title: Acute myeloid leukemia – Biology 2
Presenter: Michael R. McKeown, Ph.D., Senior Scientist, Translational Medicine, Syros
Abstract Number: P188
Location: IFEMA – Feria de Madrid, Poster area (Hall 7)
SY-1425 is currently in a Phase 2 clinical trial exploring its safety and efficacy as both a monotherapy and in combination with azacitidine, a standard-of-care hypomethylating agent, in subsets of AML and MDS patients with high expression of RARA pathway-associated genes RARA and IRF8.